The naked mole-rat is not much to look at: wrinkled, nearly hairless, roughly the size of a thumb. But it can live past 30 years, an almost absurd lifespan for a rodent its size. A typical lab mouse is old at two. Even more remarkable, naked mole-rats almost never develop cancer. For years, biologists at the University of Rochester have been trying to figure out why, and in a study published in Nature in 2023, they showed they could transfer a piece of that protection into ordinary mice with a single gene.
The transgenic mice carrying the naked mole-rat gene lived longer, aged more gracefully, and none of them developed cancer during the study. Nearly three years later, the findings remain one of the most striking demonstrations that a longevity trait from one species can be transplanted into another, and they continue to shape how researchers think about aging, cancer, and the molecules that connect the two.
A sugar molecule at the center of it all
The gene in question, called nmrHas2, codes for an enzyme that produces hyaluronan, a long-chain sugar molecule that fills the spaces between cells. Humans and mice make hyaluronan too, but naked mole-rats produce a version with an unusually high molecular mass, and they produce a lot of it. That distinction turns out to matter enormously.
The trail to this discovery stretches back more than 15 years. In 2009, Vera Gorbunova and Andrei Seluanov, the husband-and-wife team leading the Rochester lab, published work in PNAS showing that naked mole-rat cells exhibit an unusually strong form of contact inhibition, the built-in brake that stops cells from piling on top of one another. That brake is one of the body’s primary defenses against tumor formation, and in naked mole-rats, it was far more sensitive than in mouse or human cells.
By 2013, the same lab had pinpointed the molecule responsible. When they removed high-molecular-mass hyaluronan from naked mole-rat cells, or ramped up the enzyme that breaks it apart, the cells lost their cancer resistance and became susceptible to malignant transformation. The finding, also published in Nature, earned the team the distinction of having their work named Science magazine’s “Breakthrough of the Year” runner-up.
Later quantitative studies confirmed that naked mole-rats carry higher concentrations of this oversized hyaluronan across multiple tissue types and in their blood plasma compared with mice and guinea pigs. Follow-up research showed that the very-high-molecular-mass form does more than fill space: it actively shields cells from damage by dampening inflammatory responses and promoting survival under stress. It is a structural molecule that doubles as a signaling molecule.
What happened in the mice
For the 2023 experiment, Gorbunova and Seluanov’s team generated transgenic mice that overexpressed the naked mole-rat version of the HAS2 gene. The mice produced elevated levels of high-molecular-mass hyaluronan in their tissues, mimicking what happens naturally inside a naked mole-rat.
The results were broad. The transgenic mice showed a roughly 4.4 percent increase in median lifespan compared with controls, a modest but statistically significant gain for a single-gene intervention. More notable were the healthspan improvements: lower levels of chronic inflammation, better gut barrier integrity, and overall tissue condition that looked younger than their chronological age would predict. When researchers challenged the mice with chemicals known to induce cancer, the transgenic animals resisted tumor formation at rates far above those of normal mice. Spontaneous cancers, the kind that arise naturally with age, were also markedly reduced. In the study cohort, none of the transgenic mice developed cancer.
Pathology records from zoo populations of naked mole-rats provide supporting context. A retrospective survey of captive animals documented the types of lesions found in the species and was directly referenced in the 2013 paper. Those records reinforce the broader claim that naked mole-rats rarely develop cancer, though they also show the species is not completely immune: rare neoplasms have been reported. The headline phrase “never got cancer” applies specifically to the transgenic mice in this experiment, not as a universal rule for naked mole-rats.
What scientists still do not know
The Nature study is a single experiment in one strain of laboratory mice. Whether the same gene transfer would produce identical results in other strains, in larger mammals, or eventually in humans remains untested. No primary research data exist on how human cells respond to nmrHas2 overexpression. The University of Rochester’s own public summary frames the work as a proof of concept, not a preclinical therapy, and no regulatory filings or human trial plans have been announced.
As of June 2026, no independent replication of the transgenic mouse results has appeared in the published literature. That does not invalidate the findings, but replication by outside labs is a standard benchmark before the scientific community treats a result as settled.
Mechanistic questions are also unresolved. The transgenic mice showed reduced inflammation and improved gut function, but the precise chain of molecular events connecting elevated hyaluronan to those outcomes has not been fully mapped. Researchers do not yet know whether the benefits come primarily from hyaluronan’s direct interaction with cell-surface receptors like CD44, from structural changes in the extracellular matrix that alter how tissues age, or from some interplay of both. The cytoprotective signaling documented in follow-up studies offers clues, not a complete pathway.
No data exist on multi-generational effects. The transgenic mice were observed over their own lifetimes, but whether the benefits would hold, fade, or produce unexpected developmental trade-offs in subsequent generations has not been studied. Germline transmission of modified genes can sometimes reveal problems that do not surface in first-generation animals.
Safety over long time horizons is another open question. The mice in the study showed no obvious adverse effects, but chronically elevated hyaluronan could, in principle, interfere with wound healing, organ function, or immune regulation. In humans, dysregulated hyaluronan metabolism has been linked to fibrotic conditions. Whether decades of elevated very-high-molecular-mass hyaluronan would be benign, beneficial, or harmful is something only long-term studies in multiple species can answer.
The distance between mice and medicine
Even if the biology holds up perfectly, translating a gene-transfer approach into something a doctor could offer a patient involves enormous practical hurdles. Gene therapies currently on the market for other conditions carry price tags ranging from hundreds of thousands to millions of dollars per patient, reflecting the complexity of manufacturing and delivery. There is no indication yet of what a hyaluronan-based intervention would look like: systemic gene therapy, localized delivery to specific tissues, or periodic infusions of synthetic high-molecular-mass hyaluronan. Each route carries different safety, regulatory, and cost implications that have not been explored.
It is also worth remembering that naked mole-rats are deeply unusual animals, shaped by millions of years of adaptation to underground life with low oxygen, stable temperatures, and eusocial colony structures resembling those of insects more than mammals. Their longevity and cancer resistance almost certainly arise from a suite of traits working together, of which high-molecular-mass hyaluronan is one component. The fact that transplanting a single gene into mice recapitulated several benefits is striking, but it does not mean human aging is governed by the same levers or that one molecular adjustment will offer comparable protection.
What the Rochester team has demonstrated, and what holds up well under scrutiny nearly three years on, is that a specific molecule from an extreme species can meaningfully alter lifespan and cancer risk in a standard laboratory mammal. That is a genuine advance in understanding the biology of aging. The gap between that advance and a treatment people can use remains wide, but the direction of the research, from a wrinkled, thumb-sized rodent to a molecular mechanism to a transferable gene, is one of the more compelling arcs in modern gerontology.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
